EurekAlert! -
8 Oct 2017 06:00
(Cornell University) Certain proteins in the influenza virus remain constant year after year. Cornell University researchers are taking one of those conserved proteins, Matrix-2 (M2), and packaging it in a nanoscale, controlled-release 'capsule' in an attempt to create a quick-acting, long-lasting, multi-strain vaccine against pandemic influenza A.
Share this Article
Comment on this Article
Please to comment